84315-24-2

Usage

Uses

3-(3,5-Difluorophenyl)propionic acid is used as intermediate in pharmaceuticals.

Upstream product

• 101471-20-9 2-bromo-4,6-difluoroaniline hydrobromide 
• 367-25-9 2,4-difluorophenylamine 
• 64248-63-1 3,5-difluorobenzonitrile 
• 461-96-1 3,5-difluorobromobenzene 
• 32085-88-4 3,5-difluorobenzaldehyde 
• 923977-12-2 5-(3,5-difluoro-benzyl)-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 163978-51-6 ethyl 3-(3,5-difluorophenyl)propionate 
• 84315-23-1 3,5-difluorocinnamic acid 
• 84315-23-1 (trans)-3-(3,5-difluorophenyl)acrylic acid 

Downstream Products

• 207462-72-4 3-(3,5-difluorophenyl)propanal 
• 105219-37-2 3-(3,5-difluorophenyl)propan-1-ol 
• 531521-49-0 tert-butyl [(2S,3S)-1-(3,5-difluorophenyl)-3,4-dihydroxybutan-2-yl]carbamate 
• 388071-27-0 tert-butyl (1S)-2-(3,5-difluorophenyl)-1-[(2S)-oxiranyl]ethylcarbamate 
• 362480-04-4 tert-butyl {(S)-2-(3,5-difluorophenyl)-1-[(R)-oxiran-2-yl]ethyl}carbamate 
• 877078-49-4 (S)-4-benzyl-3-(3-(3,5-difluorophenyl)propanoyl)oxazolidin-2-one 

Relevant academic research and scientific papers

Synthetic method of 7-fluoro-5-hydroxy-2,3-dihydro-1hydrogen-indene-1-one

The invention relates to a synthetic method of 7-fluoro-5-hydroxy-2,3-dihydro-1hydrogen-indene-1-one. The technical problem that there is no synthetic method suitable for industrialization at present is mainly solved. The synthetic method of the invention

Substituted Tetrahydroisoquinolines as Beta-secretase Inhibitors

There is provided a series of tetrahydroisoquinoline diaminopropane compounds of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R, R8 and R9 are as defined herein, their pharmaceutical compositi

Potent pyrrolidine- and piperidine-based BACE-1 inhibitors

Based on lead compound 1 identified from the patent literature, we developed novel patentable BACE-1 inhibitors by introducing a cyclic amine scaffold. Extensive SAR studies on both pyrrolidines and piperidines ultimately led to inhibitor 2f, one of the m

Efficient synthesis of halo indanones via chlorosulfonic acid mediated Friedel-Crafts cyclization of aryl propionic acids and their use in alkylation reactions

Several halo indanones were synthesized from benzyl Meldrum's acid derivatives in two steps. Although several Lewis acids are effective for the Friedel-Crafts ring-closing reaction on more electron-rich arenes, in the case of the electron-deficient arenes this chemistry is not efficient. Here it is reported that chlorosulfonic acid (used as solvent) is an efficient reagent for cyclization of electron-withdrawing arenes. These molecules are potentially useful for subsequent alkylation reactions. The selective alkylation of 5,7-dibromo indanone is demonstrated using Pd-catalyzed Grignard coupling to provide monoalkylated indanone in good yield.

Novel gamma-lactams as beta-secretase inhibitors

There is provided a series of novel substituted gamma-lactams of Formula (I) or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, R5 and R6 as defined herein, their ph

NOVEL ISOPHTHALATES AS BETA-SECRETASE INHIBITORS

There is provided a series of substituted isophthalates of formula (I) or a stereoisomer thereof; or a pharmaceutically acceptable salt thereof, wherein W, R3, R5 and R6 as defined herein, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present disclosure is directed to compounds useful in the treatment of neurological disorders related to β-amyloid production, such as Alzheimer's disease and other conditions affected by anti-amyloid activity.

CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R is-C(O)-N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer’s disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, and N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT

Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is formula (I) X is -0-, -C(R14)2- or -N(R)-; Z is -C(R14)2- or -N(R)-; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, -OR35, -N(R24)(R25)or -SR35; R41 is alkyl, cycloalkyl, -S02(alkyl), -C(O)-alkyl, -C(O)-cycloalkyl or -alkyl-NH-C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula (I). Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS

The present invention provides a compound of the formula: Formula (I); or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient, and methods for treating physiological disorders, particularly congestive heart disease, hypertension, and atherosclerosis, comprising administering to a patient in thereof an effective amount of a compound of Formula I. X-16125

Epoxidation with Dioxiranes derived from 2-Fluoro-2-substituted-1-tetralones and -1-indanones

Homochiral 2-fluoro-2-substituted-1-tetralones (10a, 10b, 13) and ethyl 2-fluoro-1-indanone-2-carboxylate (16) have been isolated.The dioxirane derivatives of these ketones have been prepared in situ, and have been shown to epoxidise alkenes but not enantioselectively.The dioxirane derivative of methyl 2,5,7-trifluoro-1-indanone-2-carboxylate (18) has been shown to be comparatively efficient in epoxidation.